Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma

Ads

You May Also Like

Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers

                                                                  NANOBIOTIX PARTNERS WITH WEILL CORNELL MEDICINE ON PRE-CLINICAL STUDIES TO EVALUATE THE IMPACT ...